Jin Medical International Ltd. (ZJYL) 股票分析

公司概述

Jin Medical International Ltd. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it engages in the design, development, manufacture, and sale of wheelchairs and other living aids for individuals with disabilities, the elderly, and those recovering from injury. The company's product portfolio extends to wheelchair components such as wheels and brakes, as well as oxygen concentrators, serving a specialized market segment with essential mobility and respiratory support solutions. In terms of scale, the company maintains a market capitalization of $17.22M, reports annual revenue of $20.69M, and employs 273 individuals to execute its operations. These valuation and revenue figures indicate that Jin Medical International Ltd. is a small-cap entity with a relatively modest revenue footprint compared to larger peers in the global medical device industry.

财务健康

The company reported a trailing twelve-month revenue of $20.69M and a net income of $1.19M, while generating an EBITDA of $851,585. The significant disparity between the revenue figure of $20.69M and the net income of $1.19M reveals a cost structure where operating expenses, including cost of goods sold and overhead, consume approximately 94.2% of total revenue before tax and other non-operating items. However, the free cash flow stands at -$5,111,959, which indicates a substantial cash outflow relative to cash generation from operations and investing activities, suggesting limited financial flexibility for capital allocation or debt repayment in the current period. The gross margin is recorded at 30.2%, indicating that the company retains roughly 30 cents for every dollar of sales after direct production costs. The operating margin sits at 9.8%, reflecting the efficiency of core business operations before interest and taxes, while the profit margin of 5.8% demonstrates the final return on every dollar of sales after all expenses are accounted for. On the balance sheet, the company holds $29.63M in cash against $18.91M in debt, resulting in a debt-to-equity ratio of 63.95, which suggests a leveraged capital structure where equity financing is significantly lower than the debt obligations. Despite the debt load, the current ratio of 1.85 indicates that the company possesses 1.85 times more current assets than current liabilities, pointing to adequate short-term liquidity to meet its immediate financial obligations. Return on Equity is calculated at 4.8% and return on assets at 0.8%, metrics that reveal management effectiveness is currently constrained, with returns generated on shareholder capital and total assets being quite low relative to the invested base.

估值评估

The trailing twelve-month P/E ratio is 11.00, whereas the forward P/E is listed as N/A, implying that future earnings estimates are either unavailable or insufficient to calculate a projected multiple, which creates a valuation gap that prevents direct comparison with forward-looking peer valuations. The price-to-book ratio stands at 0.58, indicating that the market values the company at less than its book value, suggesting a discount relative to the net asset position rather than a market premium. Additionally, the price-to-sales ratio is 0.83 and the EV/EBITDA multiple is 7.55; these alternative valuation metrics suggest that the company is priced conservatively on a revenue basis but carries a moderate enterprise value relative to its earnings before interest, taxes, depreciation, and amortization. Over the past year, the stock has exhibited significant price volatility, trading between a 52-week high of $19.70 and a 52-week low of $1.64. Given the wide range between $19.70 and $1.64, the current trading price sits at a level that reflects substantial downside from the yearly peak but remains above the absolute floor, highlighting the asset's sensitivity to market sentiment. The beta value is 9.37, which is exceptionally high and indicates that the stock's price volatility is nearly ten times greater than the broader market, making it a high-risk investment vehicle relative to the overall market index.

Growth & Income

Recent performance data shows revenue growth of -16.5% year-over-year and earnings growth of -32.0% year-over-year, indicating that the company is currently experiencing contraction in both top-line sales and profitability. The rate of decline in earnings is steeper than the decline in revenue, as the 32.0% drop in earnings contrasts with the 16.5% drop in revenue, which implies that the company's cost structure or expense levels may be becoming increasingly inefficient or that fixed costs are being amplified by the shrinking revenue base. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated earnings are retained within the company rather than distributed to shareholders. Consequently, the growth and income profile is characterized by negative momentum in both revenue and earnings, coupled with a lack of income distribution, requiring investors to rely solely on potential future operational improvements or asset appreciation for returns.